Lesniak, Robert K.; Nichols, R. Jeremy; Schonemann, Marcus; Zhao, Jing; Gajera, Chandresh R.; Lam, Grace; Nguyen, Khanh C.; Langston, J. William; Smith, Mark; Montine, Thomas J. published the artcile< Discovery of 1H-Pyrazole Biaryl Sulfonamides as Novel G2019S-LRRK2 Kinase Inhibitors>, Electric Literature of 660867-80-1, the main research area is pyrazole biaryl sulfonamides preparation G2019S LRRK2 kinase inhibitor.
G2019S (GS) is the most prevalent mutation in the leucine rich repeat protein kinase 2 gene (LRRK2), a genetic predisposition that is common for Parkinson’s disease, as well as for some forms of cancer, and is a shared risk allele for Crohn’s disease. GS-LRRK2 has a hyperactive kinase, and although numerous drug discovery programs have targeted LRRK2 kinase, few have reached clin. development. We report the discovery and preliminary development of an entirely novel structural class of potent and selective GS-LRRK2 kinase inhibitors: biaryl-1H-pyrazoles.
ACS Medicinal Chemistry Letters published new progress about Crohn disease. 660867-80-1 belongs to class alcohols-buliding-blocks, and the molecular formula is C12H18BNO2, Electric Literature of 660867-80-1.
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts